Facing ‘uncertainty on steroids,’ biotech dealmakers tread more cautiously
Andrew Merken, Shareholder in our Venture Capital and Emerging Growth Companies Group, addresses the market's uncertainty, complicating biotechnology dealmaking as companies find it challenging to agree on pricing.
